Use this banner to inform your users of
something important.
HAII's 'Alzguard-T' Selected as an Innovation Product by the Public Procurement Service
HAII's cognitive function evaluation and improvement service, Alzguard-T, was chosen as an innovation product by Korea's Public Procurement Service, designed to help prevent dementia through brain tests and training for older adults.
Read more >
HAII's 'Repeech' Gains US Approval for Key Clinical Trials
HAII Corporation has received US Institutional Review Board (IRB) approval from the Massachusetts General Hospital to
initiate clinical trials for its digital speech rehabilitation therapeutic, “Repeech,” aimed at assisting stroke patients in
regaining speech capabilities.
HAII Secures Second Place in KHIDI-Roche Diagnostics Day's "New Impact Project"
HAII's strong performance in the competition highlights its potential for global expansion in the digital biomarker and AI healthcare sectors, positioning the company for significant international growth.
HAII Highlights Role of Explainable AI in Digital Health at XAI Workshop 2024
At the ‘KCC XAI Workshop 2024,’ HAII presented its advancements in digital therapeutics, showcasing how explainable AI enhances patient trust and clinical outcomes, particularly through its speech therapy app, “Repeech,” which leverages XAI for improved transparency and personalized treatment.
HAII Signs Comprehensive Partnership Agreement with IM Rehabilitation Hospital
HAII and IM Rehabilitation Hospital have entered into a collaboration to develop and commercialize the digital therapeutic "Repeech" for stroke-related speech and cognitive rehabilitation.
HAII Secures MFDS Approval for Confirmatory Clinical Trials of Dementia Diagnostic Digital Device
HAII becomes the first in South Korea to receive MFDS approval for clinical trials of its diagnostic digital device, Alzguard, which uses digital biomarkers like voice, eye movement, and cognitive response for early detection.
HAII Receives Approval from the MFDS for Confirmatory Clinical Trials of ‘Repeech’
HAII has secured approval from South Korea’s Ministry of Food and Drug Safety (MFDS) to conduct confirmatory clinical trials for its digital speech therapy solution ‘Repeech,’ designed to aid post-stroke patients in speech rehabilitation through a mobile app.
Terms of Use I Privacy Policy
@Copyright 2022. All Right Reserved. Hosted by Imweb
Terms of Use l Privacy Policy
@Copyright 2024. All Right Reserved. Hosted by Imweb
